Abstract
Exogenous oxytocin administration in obese mice, rats, and monkeys was shown to induce sustained weight loss, mostly due to a decrease in fat mass, accompanied by an improvement of glucose metabolism. A pilot study in obese humans confirmed the weight-reducing effect of oxytocin. Knowledge about circulating oxytocin levels in human obesity might help indicating which obese subjects could potentially benefit from an oxytocin treatment. Conclusive results on this topic are missing. The aim of this study was to measure circulating oxytocin levels in lean (n = 37) and obese (n = 72) individuals across a wide range of body mass index (BMI) values (18.5–60 kg/m2) and to determine the impact of pronounced body weight loss following gastric bypass surgery in 12 morbidly obese patients. We observed that oxytocin levels were unchanged in overweight and in class I and II obese subjects and only morbidly obese patients (obesity class III, BMI > 40 kg/m2) exhibited significantly higher levels than lean individuals, with no modification 1 year after gastric bypass surgery, despite substantial body weight loss. In conclusion, morbidly obese subjects present elevated oxytocin levels which were unaltered following pronounced weight loss.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Blevins JE, Baskin DG. Translational and therapeutic potential of oxytocin as an anti-obesity strategy: Insights from rodents, nonhuman primates and humans. Physiol Behav. 2015;152(Part B):438–49.
Gimpl G, Fahrenholz F. The oxytocin receptor system: structure, function, and regulation. Physiol Rev. 2001;81:629–83.
Deblon N, Veyrat-Durebex C, Bourgoin L, Caillon A, Bussier AL, Petrosino S, et al. Mechanisms of the anti-obesity effects of oxytocin in diet-induced obese rats. PLoS ONE. 2011;6:e25565.
Zhang H, Wu C, Chen Q, Chen X, Xu Z, Wu J, et al. Treatment of obesity and diabetes using oxytocin or analogs in patients and mouse models. PLoS ONE. 2013;8:e61477.
Altirriba J, Poher AL, Caillon A, Arsenijevic D, Veyrat-Durebex C, Lyautey J, et al. Divergent effects of oxytocin treatment of obese diabetic mice on adiposity and diabetes. Endocrinology. 2014;155:4189–201.
Blevins JE, Graham JL, Morton GJ, Bales KL, Schwartz MW, Baskin DG, et al. Chronic oxytocin administration inhibits food intake, increases energy expenditure, and produces weight loss in fructose-fed obese rhesus monkeys. Am J Physiol Regul Integr Comp Physiol. 2015;308:R431–8.
Zhang G, Cai D. Circadian intervention of obesity development via resting-stage feeding manipulation or oxytocin treatment. Am J Physiol Endocrinol Metab. 2011;301:E1004–12.
Roberts ZS, Wolden-Hanson T, Matsen ME, Ryu V, Vaughan CH, Graham JL, et al. Chronic hindbrain administration of oxytocin is sufficient to elicit weight loss in diet-induced obese rats. Am J Physiol Regul Integr Comp Physiol. 2017;313:R357–R71.
Maejima Y, Aoyama M, Sakamoto K, Jojima T, Aso Y, Takasu K, et al. Impact of sex, fat distribution and initial body weight on oxytocin’s body weight regulation. Sci Rep. 2017;7:8599.
Morton GJ, Thatcher BS, Reidelberger RD, Ogimoto K, Wolden-Hanson T, Baskin DG, et al. Peripheral oxytocin suppresses food intake and causes weight loss in diet-induced obese rats. Am J Physiol Endocrinol Metab. 2012;302:E134–44.
Plante E, Menaouar A, Danalache BA, Yip D, Broderick TL, Chiasson JL, et al. Oxytocin treatment prevents the cardiomyopathy observed in obese diabetic male db/db mice. Endocrinology. 2015;156:1416–28.
Gajdosechova L, Krskova K, Segarra AB, Spolcova A, Suski M, Olszanecki R, et al. Hypooxytocinaemia in obese Zucker rats relates to oxytocin degradation in liver and adipose tissue. J Endocrinol. 2014;220:333–43.
Swaab DF, Purba JS, Hofman MA. Alterations in the hypothalamic paraventricular nucleus and its oxytocin neurons (putative satiety cells) in Prader–Willi syndrome: a study of five cases. J Clin Endocrinol Metab. 1995;80:573–9.
Qian W, Zhu T, Tang B, Yu S, Hu H, Sun W, et al. Decreased circulating levels of oxytocin in obesity and newly diagnosed type 2 diabetic patients. J Clin Endocrinol Metab. 2014;99:4683–9.
Coiro V, Passeri M, Davoli C, d’Amato L, Gelmini G, Fagnoni F, et al. Oxytocin response to insulin-induced hypoglycemia in obese subjects before and after weight loss. J Endocrinol Invest. 1988;11:125–8.
Stock S, Granstrom L, Backman L, Matthiesen AS, Uvnas-Moberg K. Elevated plasma levels of oxytocin in obese subjects before and after gastric banding. Int J Obes. 1989;13:213–22.
Szulc P, Amri EZ, Varennes A, Panaia-Ferrari P, Fontas E, Goudable J, et al. High serum oxytocin is associated with metabolic syndrome in older men—The MINOS study. Diabetes Res Clin Pract. 2016;122:17–27.
Schorr M, Marengi DA, Pulumo RL, Yu E, Eddy KT, Klibanski A, et al. Oxytocin and its relationship to body composition, bone mineral density, and hip geometry across the weight spectrum. J Clin Endocrinol Metab. 2017;102:2814–24.
Guessous I, Bochud M, Theler JM, Gaspoz JM, Pechere-Bertschi A. 1999–2009 Trends in prevalence, unawareness, treatment and control of hypertension in Geneva, Switzerland. PLoS ONE. 2012;7:e39877.
World Health Organization. Obesity: preventing and managing the global epidemic. Report of a WHO Consultation. WHO Technical Report Series 894. Geneva: World Health Organization; 2000.
R Core Team. A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2017. Available from: URL http://www.R-project.org/.
Faul F, Erdfelder E, Lang AG, Buchner A. G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods. 2007;39:175–91.
McCullough ME, Churchland PS, Mendez AJ. Problems with measuring peripheral oxytocin: can the data on oxytocin and human behavior be trusted? Neurosci Biobehav Rev. 2013;37:1485–92.
Szeto A, McCabe PM, Nation DA, Tabak BA, Rossetti MA, McCullough ME, et al. Evaluation of enzyme immunoassay and radioimmunoassay methods for the measurement of plasma oxytocin. Psychosom Med. 2011;73:393–400.
Brandtzaeg OK, Johnsen E, Roberg-Larsen H, Seip KF, MacLean EL, Gesquiere LR, et al. Proteomics tools reveal startlingly high amounts of oxytocin in plasma and serum. Sci Rep. 2016;6:31693.
Leng G, Sabatier N. Measuring oxytocin and vasopressin: bioassays, immunoassays and random numbers. J Neuroendocrinol. 2016;28. https://doi.org/10.1111/jne.12413.
Lawson EA. The effects of oxytocin on eating behaviour and metabolism in humans. Nat Rev Endocrinol. 2017;13:700–9.
Akour A, Kasabri V, Boulatova N, Bustanji Y, Naffa R, Hyasat D, et al. Levels of metabolic markers in drug-naive prediabetic and type 2 diabetic patients. Acta Diabetol. 2017;54:163–70.
Al-Rawashdeh A, Kasabri V, Bulatova N, Akour A, Zayed A, Momani M, et al. The correlation between plasma levels of oxytocin and betatrophin in non-diabetic and diabetic metabolic syndrome patients: a cross sectional study from Jordan. Diabetes Metab Syndr. 2017;11:59–67.
Amico JA, Seif SM, Robinson AG. Oxytocin in human plasma: correlation with neurophysin and stimulation with estrogen. J Clin Endocrinol Metab. 1981;52:988--93.
Kim TW, Jeong J-H, Hong S-C. The Impact of Sleep and Circadian Disturbance on Hormones and Metabolism. Int J Endocrinol. 2015;2015:591729.
Muscelli E, Mingrone G, Camastra S, Manco M, Pereira JA, Pareja JC, et al. Differential effect of weight loss on insulin resistance in surgically treated obese patients. Am J Med. 2005;118:51–7.
Acknowledgements
We thank F Bontems for technical support, MO Boldi for statistical help, the “Bus Santé” collaborators and participants, the Swiss National Science Foundation (grant 310030_160290/1), and the HUG and the General Directorate of Health (Geneva Canton, Switzerland).
Funding
This study was supported by the Swiss National Science Foundation (grant 310030 160290/1). The “Bus Santé” study is funded by the University Hospitals of Geneva and the General Directorate of Health, Canton of Geneva, Switzerland.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
FRJ has a patent application (PCT/IB2011/052156) covering therapeutic uses of oxytocin. The other authors declare that they have no conflict of interest.
Electronic supplementary material
Rights and permissions
About this article
Cite this article
Pataky, Z., Guessous, I., Caillon, A. et al. Variable oxytocin levels in humans with different degrees of obesity and impact of gastric bypass surgery. Int J Obes 43, 1120–1124 (2019). https://doi.org/10.1038/s41366-018-0150-x
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41366-018-0150-x